Business Context and Reporting Period
Company: Accendra Health, Inc. (formerly Owens & Minor, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: A leading nationwide provider of products, technology, and services supporting health beyond the hospital. The company operates as a single reporting segment following the completion of the sale of its Products & Healthcare Services (P&HS) business on December 31, 2025, which is now reported as discontinued operations.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Revenue | $627.8 million | $673.9 million |
| Operating Income | $17.1 million | $19.8 million |
| Net Loss (Continuing Ops) | $(6.5) million | $(3.8) million |
| Net Loss (Total) | $(6.5) million | $(25.0) million |
| Adjusted EBITDA (Non-GAAP) | $58.4 million | $96.0 million |
| Free Cash Flow (Non-GAAP) | $(2.0) million | $35.6 million |
| Cash and Equivalents | $336.9 million | $59.4 million |
| Total Debt (Carrying Value) | $2.10 billion | $2.05 billion |
| Interest Expense, Net | $32.3 million | $24.2 million |
Material Changes vs. Prior Period
- Revenue Decline: Net revenue decreased by $46.1 million (6.8%) primarily due to a $42 million reduction from terminated contracts with a commercial payor, impacting sleep therapy and home respiratory therapy segments.
- Discontinued Operations: Q1 2025 included a $21.2 million loss from discontinued operations (P&HS business), whereas Q1 2026 had no discontinued operations as the sale closed in late 2025.
- Exit and Realignment: The company reported a net benefit of $23.6 million in Q1 2026, driven by a $52 million gain on the sale of patient service equipment related to the payor contract termination. This contrasts with $13.6 million in charges in Q1 2025.
- Intangible Amortization: Increased to $29.2 million from $7.6 million due to a modification of the useful life of an intangible asset following the payor contract termination notice.
- Interest Expense: Increased by $8.1 million year-over-year, largely because interest previously allocated to discontinued operations in 2025 is now fully reflected in continuing operations.
Outlook, Risks, and Management Commentary
- Balance Sheet Optimization: On May 11, 2026, the company announced commitments from creditors to exchange and extend a substantial portion of its debt. This transaction aims to refinance Term Loan A and extend the Revolving Credit Agreement maturity to 2030, addressing liquidity concerns regarding debt maturing within 12 months.
- Payor Contract Termination: The company is winding down contracts with a commercial payor representing 6% of Q1 2026 revenue. Management does not anticipate material impacts to operating income beyond March 31, 2026, from remaining terminations.
- Liquidity: Cash balances increased to $336.9 million. The company maintains a $450 million Revolving Credit Facility with $166 million available. Management expects sufficient liquidity to meet obligations following the announced debt restructuring.
- Tax Matters: The effective tax rate was 60.2% in Q1 2026 compared to 29.4% in Q1 2025, driven by changes in operational results and forecasted tax rates. The company settled a transfer pricing audit for 2015-2018 tax years in March 2026.
- Risks: Key risks include the successful execution of the debt restructuring, transition services agreements (TSA) with the P&HS buyer, and potential reimbursement changes from government and commercial payors.
Investor Verification Checklist
- Debt Restructuring Status: Verify the closing of the "Balance Sheet Optimization Transaction" announced May 11, 2026, to confirm the extension of debt maturities beyond the current 12-month horizon.
- Payor Transition: Monitor the timeline and financial impact of the wind-down of the commercial payor contract to ensure no unexpected revenue erosion occurs in subsequent quarters.
- Receivables Sale Program: Review the utilization and terms of the Amended Receivables Sale Program ($150 million capacity) as a key liquidity source.
- Intangible Asset Amortization: Assess the long-term impact of the accelerated amortization schedule ($29 million in Q1) on future operating margins.
- Tax Liability: Confirm the final settlement amount for the 2019-2022 tax years related to the ongoing IRS transfer pricing matter.